Pharming Group (OTCMKTS:PHGUF) Shares Gap Up - Should You Buy?

Key Points

• Shares gapped up 15.9%, opening at $1.75 after a $1.51 close, with light trading volume of 1,648 shares on the move.
• The company reported quarterly EPS of $0.01 and revenue of $106.5M, beating analysts' revenue estimate of $89.72M, though net margin was slim at 0.71%.
• Pharming is a Netherlands-based rare-disease biopharma known for RUCONEST, with a $1.17B market cap, high trailing PE (~175), low beta (0.42) and strong liquidity (current ratio 3.16, quick ratio 2.39).

Pharming Group NV (OTCMKTS:PHGUF - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $1.51, but opened at $1.75. Pharming Group shares last traded at $1.75, with a volume of 1,648 shares traded.

Pharming Group Trading Up 15.9%

The firm has a market capitalization of $1.17 billion, a PE ratio of 175.18 and a beta of 0.42. The company's 50-day moving average price is $1.66 and its 200-day moving average price is $1.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.39 and a current ratio of 3.16.

Pharming Group (OTCMKTS:PHGUF - Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter. The business had revenue of $106.50 million during the quarter, compared to analysts' expectations of $89.72 million. Pharming Group had a net margin of 0.71% and a return on equity of 1.12%.

Pharming Group Company Profile

Pharming Group NV is a Netherlands-based biopharmaceutical company specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988 and headquartered in Leiden, the company leverages transgenic technology to produce recombinant proteins, with its flagship product RUCONEST (recombinant C1 esterase inhibitor) indicated for the treatment of acute hereditary angioedema (HAE) attacks. RUCONEST is approved and marketed in the United States, Europe and several other territories through partnerships with leading specialty pharmaceutical companies.

Beyond RUCONEST, Pharming maintains a diversified pipeline targeting unmet needs in rare and ultra-rare disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.